PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price dropped 8.8% during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $78.00 to $75.00.

WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, Marketbeat reports.

WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal ...

PTC Therapeutics (PTCT) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued a positive opinion on the marketing ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its ...